Clinicians like m yself feel a sense of pressure because things change so slowly for the patient in spite of the volume o f current research. This is currently the case in the chemotherapy o f leishmaniasis where the drug formulations used in the first line treatm ent have not changed for four decades. N either is a practical altemative on the horizon. There is no money to be made in treating the poor people o f rural areas suffering from this disease. The small efforts that have been extended in this direction have not m et with success. Therefore we m ust try to use antimonials more efficiently for the benefit o f the patient and this is the chief purpose of this review.
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IN T R O D U C T IO N
Clinicians like m yself feel a sense of pressure because things change so slowly for the patient in spite of the volume o f current research. This is currently the case in the chemotherapy o f leishmaniasis where the drug formulations used in the first line treatm ent have not changed for four decades. N either is a practical altemative on the horizon. There is no money to be made in treating the poor people o f rural areas suffering from this disease. The small efforts that have been extended in this direction have not m et with success. Therefore we m ust try to use antimonials more efficiently for the benefit o f the patient and this is the chief purpose of this review.
H IST O R Y
W e are indebted to D r. Edgard de Cerqueira Falcão23 for a monograph summarising the contributions of G aspar V ianna with a collection of his scientific papers. The original communication on the use of tartar emetic in cutaneous and mucosal leishma niasis is reproduced72. A lso, in a less well known paper, V ianna illustrates a very good result in a patient with severe mucosal d i s e a s e 7 3 . H e used a 1% solution of tartar emetic although the origin of the drug is not stated. Early preparations of tartar emetic were made by allowing antimony goblets to stand with white wine and extracting the supem atant. Confirmation of Vianna's favourable results followed in several Brazilian publications6 22 ^9 j n 1915 the effectiveness of tartar emetic in the treatm ent o f infantile kala-azar in Italy was reported19. The drug was then widely used during the epidemic o f kala-azar on the tea estates in A ssam 45. Núcleo de M edicina T ropical e N utrição, Universidade de Brasília -70910 B rasília-D F, Brasil.
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The m ain support over the years for these clinicai studies has been from a U nited States Public Service G ra n t(A I 16282), adm inistered by the D epartm ent of International M edicine, Com ell M edicai College, N ew York.
F o r those of us who have used tartar emetic it is obvious that its severe side effects made an altemative desirable. Bram achari in 1920 developed the first pentavalent antimonial: urea stibamine55. A more stable pentavalent antimonial by Schmidt in Germany in 1936 under the name Solustibosan (sodium antimonyl (V) gluconate63) had the advantage over the earlier N eostibosan in that it was stable in water and could be stored in solution until ready for use. A lso it could be given intramuscularly, intravenously and subcutaneously since it was not irritant to tissues even in a hypertonic solution. It was first produced by Bayer and shown to be effective in kala-azar in índia and China3646. The W ellcome product Pentostam is sodium antimony gluconate. A n altemative penta valent antimonial, G lucantim e (N-methyl-glucamine antimoniate) was developed at the end of the Second W orld W ar. E arly studies of its efficacy in both cutaneous and visceral leishmaniasis appeared in French literature21 57 . Its value in patients with mucosal lesions was reported from Brazil in 195215. Today G lucantim e is produced by Rhodia in Brazil and is widely used. Pentostam is not available here.
The mode of action of these drugs in leishmaniasis is unknown.
G lucantim e and Pentostam
These are the only two pentavalent antimonials available commercially. Both are initially manufactured as white powders (approximately 34% antimony content) and are readily soluble in water. Both solution are best kept in the dark since they may undergo chemical change if exposed to the light.
Since they don't have defined chemical formulae they are difficult to standardise. Steck67 gives the formulae for the two compounds illustrated in F i gure 1. It has been suggested that toxicity is not necessarily related to antimony content31. Activity and toxicity may vary from batch to batch3. The author has personal experience of this with both drugs. It is worth citing a comment on the pentavalent antimonials32. " These drugs, under whatever name, are simply solutíons o f antimony pentoxide in a highly hydroxylated organic medium and making them is cookery, not chemistry. One can make such a drug to contam any amount of antimony, and to have any degree of toxicity; one has to choose a method o f making it which provides a reasonable product, with reasonable activity and reasonably low toxicity. W hen one puts it into a patient about 80 or 90% o f the antimony it contains is excreted by the kidneys in the first few hours, so one is relying on w hat is left in the animal, soaked into the tissue cells, which later reduce it to trivalent antimony (Goodw in & Page 1943). This is the killer, hopefully, o f the parasite but unfortunately sometimes of the patient." A variation in antileishmanial activity in different ampoules of Glucantimme has been noted in an in vitro system43. A revaluation of this problem is long overdue since pentavalent antimonials rem ain the drugs o f choice1. There appears to be little different in action between Pentostam and G lucantim e8 although a good comparative trial has yet to be done.
G lucantim e is m arketed in 5 ml ampoules containing 1.5 grams o f the drug meglumine antimoniate and 425 mg pentavalent antimony (the equivalent o f 85 Sbv mg per ml). Pentostam is presented in 100 ml flasks each ml containing 100 mg Sbv. The ampoule has an advantage over the flask for trçatm ent in the field since ampoules are less liable to contamination by local people applying repeated injections for patients. These applicators usually can only give intram uscular injections. T he volume using Pentostam is 15% less, reducing local pain a little when large doses are applied intramuscularly.
I t is difficult to get accurate information on sales o f these drugs from the respective companies but it can't be th at good, since both companies have tried to term inate manufacture, possibly because o f the difficulties o f standardising these products. Only an outcry from the medicai profession, who have no real altem ative for treatm ent, prevented this measure. Certainly in our field area the price o f one ampoule of G lucantim e to the patient has been as high as two A m erican dollars afteç various intermediaries have taken their cut. In June 1984 a bottle o f Pentostam cost £63 over the counter in England (R A N eal: personal communication). This explains why patients forced to self treatm ent buy so little G lucantim e; often less than ten ampoules. T hey simply cannot afford more. O ur recommendation for a patient with mucos al disease weighing 60 kilograms in the initial treatm ent course is 120 ampoules of G lucantim e as a total dose. G ovem m ents are aware of this problem of cost. índia and C hina faced with epidemics of kala-azar made their own pentavalent antimonial. Brazil recently completed the last steps of G lucantim e fabrication at a govem ment levei but the resulting product was not satisfactory. In Brazil and Venezuela the ministry of health provides G lucantim e free to applying physicians. W e benefit greatly from this arrangem ent in our field clinic in Três Braços, Bahia, but even for us, a field project with govem ment support, often G lu cantim e is not available. The cost buying hundred of thousands o f ampoules m ust raise difficulties when considering other health prioritíes. A n attem pt has been made to map in Brazil the importance of leishmaniasis based on notifications and requests for G lucantim e but this certainly underestim ates the size o f the p ro b le m^. 
Absorption, distribution a n d excretion
Some aspects have been reviewed by Beveridge^. Many antimony drugs like tartar emetic are too irritant to be given by mouth but P anayotatou5 3 cured a case of infantile kala-azar by instillation per rectum of a trivalent salt. In our current situation perhaps her observations should be followed up and the value of the oral route for pentavalent antimonials reviewed in suitable animal experiments.
Parenteral pentavalent antimony achieves peak blood leveis within an hour. Intram uscular injection results in a slightly lower, later peak than intravenous application but this makens little difference12. The drug is rapidly excreted in the urine2^ 51 A fter 6 hours blood leves have fallen to less than 1% of peak values and more than 80% has been excreted in the urine59. Thus patients are voiding the greater part of the drug they receive. This raises the interesting possibility of interfering with this rapid excretion and therefore using smaller doses to achieve the same effect. Because of the potential toxicity o f antimonials this implies another series o f animal studies. The hamster is not a good model for such studies since the kidney is composed alm ost entirely of long loop nephrons. The dog would be a more suitable model to mimic the human situation.
A bout 12% of the antim onvdose is retained with a half-life of 32.8 ± 3.8 hours12. W ith repeated injections a rise in the base line levei o f retained antimony can be observed over the initial five days of treatment. Some of this antimony is thought to be reduced to the trivalent state^O and trivalent antimony compounds m ay be less effective than pentavalent in killing Leishm ania35. M uch the retained antimony is concentrated in the liver and spleen27 58 These is no information on how much o f this antimony is present in the skin or mucous membranes although it is probably a very small amount. Y et in skin or mucosal lesions it is this fraction that m ust be important. There is some rationale then for attempting local antimony treatment in skin ulcers1 65 . Some success in animais has been noted with Pentostam cream 42 which is now being tried in man. Obviously such local treatm ent is insufficient for organisms causing systemic disease or those which produce m etastatic lesions.
It is the antimony retained in the tissues which is thought to be responsible for toxic effects. Trivalent compounds bind more to tissues (eg. red cells) and their toxicity is marked in comparison to pentavalent compounds that are rapidly excreted in the urine. For this reason pentavalent antimonials are recommended today in higher uninterrupted doses than in the past.
Com plications o f antim ony therapy
W hile the toxicity of pentavalent antimonials is much less than trivalent compounds it is not negligible. M ost side effects appear at the end of courses of therapy suggesting they are the result of cumulative effects of tissue antimony. However there are exceptions. W e have seen a single intravenous dose of 5 ml Pentostam given to a man with cutaneous leishmaniasis result in profound cardiovascular collapse with marked fali in blood pressure, sweating, and clouding of conciousness. A similar dose the next day gave the same result. There was no history of previous antimony therapy especially Pentostam. F or this reason we now advise a 1 ml intravenous test dose before commencing a course of therapy. W e have reported in the literature anuria following a total dose of only 33 grams of G lucantim e drug (9.3 grams Sbv)6 1. Recently we have seen a woman with mucosal disease who developed such severe shoulder arthralgia after 8 days Pentostam therapy she could not raise her arms. This improved within a day of cessation of therapy. F urther attem pts to commence antimony therapy resulted in her developing this symptom after a single dose of antimony and treatm ent with this drug had to be abandoned7.
A n occasional complication occuring during the first week of treatm ent is oedema and erythema of granulomas, associated sometimes with haemorrhage, and we have illustrated and reported this finding in mucosal disease6®. This is a particularly serious complication if the laryngeal aperture is a already reduced. F o r this reason we recommended that a tracheostomy set be by the bed of the patient, during the first week of therapy with facilities to do an emergency tracheostomy. A similar syndrome occurs with amphotericin B therapy so it is not a drug effect. One possibility is that the death of the tissue Leishmania promotes this reaction in a manner similar to the Jarisch -Herxheim er reaction. Although corticosteroids have been recommended to control such reactions we have had no occasion to use these to date and they could have adverse effects^ 35 Simply stopping the drug for a few days is sufficient as this phenomenon never recurs.
Sampaio62 has recently analysed the occurrence of symptomatic side effects with four different antimonial schedules (Table 1) among patients admitted to our university hospital in Brasília. Common symptomatic side effects are arthralgia, myalgia, anorexia, nausea, vomiting and headache1. These side effects are com monest with high continous doses of antimony (Table 2) . H erpes infection of the skin is a recognised complication of heavy metal therapy and occurred in our earlier s e r i e s 6 2 .
A granulocytosis has been noted4 and we have seen low white blood cell counts develop while on pen tavalent antimonial therapy.
In patients receiving antimonials the biochemical side effects mentioned in T able 2 were rises in the transam inases and alkaline phosphatase suggesting hepatocellular dysfunction^2. Only in two patients taking antimonials was a rise in blood urea the biochemical abnormality. G lom erular lesions due to toxicity are very rare in our experience but a tubular defect is common with high dose antimony^O. W e have studied tubular function after antimony therapy and it recovers rapidly in nearly ali p atien ts^'. The tubular defect appears to be based on two mechanisms, interference with the action of antidiuretic hormone and a direct toxic effect on the tubular cells26. If lower doses of antimony are used this renal complication is uncommon34.
Electrocardiographic abnormalities are ajso listed in Table 2 and appear to be more frequent with schedule A. In our early hospital studies we tried to give this dose schedule continuously but reported electrocardiographic changes in ali three patients after 20 days continuous therapy6^. 28 mg Sbv/kg/day is approaching the toxic single dose of 30 mg Sbv/kg/ day1. The frequency of cardiac arrhythmias is related to the total daily dose of antimony 14. The common E C G changes are T wave inversion and a prolonged Q T interval but rarely severe even fatal arrhythmias have occurred14
It m ust be emphasised that ali these side effects occur at high dosage in the patient with normal organ function; at lower doses electro cardiographic effects are not seen44.
M any of these side effects occur together with maximal therapy. A n illustration is our patient who resisted 30 days continuous Pentostam therapy (10 mg Sbv/kg/day) and 2.5 grams amphotericin B but was eventually cured by 85 days therapy at a daily dose of 20 mg Sbv/kilogram per day. O n the 85th day he had arthritis with effusion of the left wrist and shoulder, a palpable liver and raised transam inase and alkaline phosphatase leveis, diffuse alterations of repolarisation on the electrocardiogram and a renal tubule concentrating defect4 1.
Toxic encephalitis associated with heavy metal therapy we have not seen nor can I trace a reference in the literature associated with pentavalent afitimonials. One elderly lady in the field area who was given a daily dose in error exceeding 30 mg Sbv/kg/day of G lucan time developed peripheral neuritis and exfoliative dermatitis. Fortunately both improved after cessation of therapy. Perhaps it is worth mentioning that we have never permanently prejudiced or lost a patient as a result of pentavalent antimony therapy in spite of using relatively high doses in over 1,000 patients.
Really the situation with regard to the use of antimonials, specially in the field, has not changed from the observation of Pessoa and Barretto-^ quoted below with relation to tartar emetic.
" Clinicai experience in both visceral and cutaneous A m erican leishmaniasis shows that the m ost satisfactory results are obtained using large doses in the shortest periods of time even if certain symptoms of intolerance are produced. We wish to call the attention of clinicians in general to this point for our experience shows that, many clinicians in the interior of the State, where the disease is prevalent, use, for fear of producing accidents due to intolerance to tartar emetic, excessively small doses of the product resulting in low treatment efficiency and a prolonged treatm ent tim e"^4.
D rug delivery in m an o f pentavalent antim onials
Ali drug doses are now expressed in milligrams of pentavalent antimony per kilogram per day so that schemes are standardised irrespective of the preparation1.
A s might be expected this is a most controversial area. N ot only clinicians vary widely in their opinions as to the dose o f pentavalent antimonials that should be used but even the two principal drug companies have different recommendations. For Pentostam the W ellcome Laboratories Ltd, Beckenham, England, recommend that adults (60 kg) be given intravenous or intramuscular injections of 10 mg Sbv/kg/day for 7-10 days and that 2-3 cycles be separated with ten day rest intervals if additional treatm ent is necessary. F o r Glucantime Rhodia SA,
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São Paulo, Brazil,recommend adults be given intramuscular injections of 17-28 mg Sbv/kg/day for 10-20 days followed by a 15 day rest interval and a second cycle if needed. Both recommendations are now obsolete since the work done in Kenya showed that such rest periods are pharmacologically unsound since both drugs are rapidly excreted in the urine. This work which I have reviewed e l s e w h e r e 3 9 , since it shortens treatment time, is the only practical advance for the patient in the treatm ent of leishmaniasis to appear in the last decade.
Yet one can sympathise with the drug companies since these recommendations are an enormous problem as evidence grows of differing susceptibilities to antimonials of various leishmanial species and the clinicai syndromes caused by these parasites. Unfortunately comparative studies of different taxonomically defined leshmanial infections in man where similar doses have been used do not exist in the literature although a study is being prepared from Panam a13. M any workers can't mount such studies. F or example, in our work in Central Brazil L eishm ania braziliensis braziliensis (Lbb) infection is so common we have very few other species indentifications in patients with mucocutaneous disease. Recently 1 have tried to design a simple table as a guide for antimonial use for Conn's Current Therapy, a didactic treatm ent text, and this is shown in T able 3. It represents an oversimplification and the fact is that the clinician has to exercise considerable skill in the use of antimonials taking into account the nature of the lesion, the probable infecting organism (this information is not available at the time of the treatm ent decision), the age and weight of the patient as well as any evidence of organ disfunction.
The smallest adult dose of G lucantim e recommended in Brazil is one ampoule of G lucantim e two times a w e e k 4 9 . W hile this seems homeopathic to some and cannot be recommended it is possibly the only dose available, for reasons o f cost, for a child with advanced kala-azar, anaem ic and malnourished who has to be treated at home in one of the fa v ela s in the cities of Brazil where kala-azar is currently endemic. The fact that Brazilian kala-azar responds to such a dose shows it has a high sensitivity although the relapse rate must be high. The highest daily dose advocated in Brasil is six ampoules of Glucantim e a day 1®. This is well over the toxic limit mentioned by the W orld H ealth O rganization1 for a single dose and it is curious that few toxic effects were observed. It cannot be recommended. A Brazilian M inistry of Health recommendation is one ampoule of Glucantime daily for 7-10 days; the course being repeated if necessary. In our recent experience it appears that this will close m any skin ulcers due to Lbb; but will it prevent mucosal disease? Since in the past year we have had little G lucantim e, we have many patients with Lbb who had to be treated with such a schedule (7 mg Sbv/kg/day). T hey are under longitudinal observation. W e have used four times this dose in the endemic area o f T rês Braços for years (28 m g/kg/day) and in our recently published studies mucosal relapse was almost unknown on short term follow-up37. The practical difficulties of giving such high doses under field conditions are considerable (20 cm 3 daily intramuscular dose) but they cannot be discussed here. Prata has never seen a kala-azar patient relapse in Brazil using sim ilar doses in over 100 patients (A R Prata: personal communication) but they do rarely occur^Õ 68
On the whole in terms, of frequency of treatm ent problems in hospitais in Brazil, it is mucosal leishmaniasis which causes m ost concem . Table 4 shows our results with the four antimony schedules previously mentioned in relation to mucosal disease in our hospital in Brasília63. O ur analysis of the results of treatm ent with cutaneous lesions failed to show a difference between the four schedules but there is a difference between these in mucosal patients. Such data is extremely difficult to collect due to follow-up problems and as yet it does not lend itself to statistical analysis. H owever it suggests that 20 m g/Sbv/ kilogram body weight for a m ean of 30 days is the best recommendation. Bryceson in London has recently started to use this dose twice a day to further reduce hospital stay (A D M Bryceson: personal communi cation). Evidently we still have to define optimal schedules for antimony use.
Both Pentostam and G lucantim e are best given by slow intravenous infusion over at least three minutes. N o diluent is usually necessary unless the patient develops a venous thrombosis at an inoculation site. Intram uscular injection is painful but often necessary under field conditions where no doctor can be present for daily injection. O ne lot of Glucantime used in Três Braços produced several muscle abscesses. Pharmacokinetic studies show little diffe rence in peak serum leveis after application by these two r o u te s 1^. A n interesting study carried out at the W alter Reed Arm y M edicai Center com pared three methods o f drug delivery in A m erican soldiers with leishmaniasis. W hile ali subjects were given the same total dose of 600 mg Sbv/d ay this was administered either as a continous 24 hours infusion, in three divided eight hourly doses or as a single intravenous dose^O. The latter method was shown to be more effective in terms of cure and incidence of subjective complaints.
In patients with evidence of renal, cardiac or hepatic disease an alternative may have to be sought depending on the clinicai assessm ent of the patient. Patients with renal insufficiency become lethargic, anorexic, drowsy and weak after antimonial th e r a p y 5 9 . A ltem atives are the recommended second line drugs1 namely Pentam idine which has few renal side effects or amphotericin B which is free of hepatic toxicity and cardiac effects are only related to potassiun inbalance.
Finally even high dose pentavalent antimonial will not cure ali patients. W e have reported a girl who Treatm ent schedule A -28mg Sbv/kg/day for 10-12 days repeated 3 times with an interval of 15 days. developed mucosal granulomas during antimonial treatm ent for her skin lesion due to Lbb4®.
Unresponsiveness
In brief recent work regarding disease response to total antimony dose suggests that high continuous antimony therapy is the best approach in recalcitrant disease for a favourable response. Syndromes such as are mentioned in group C of Table 3 require this approach. This is not to say that high dose antimony will always m eet with success particularly in patients with mucosal disease^4 40 . Anergic H ansenoid leishmaniasis will fail to respond since the patient can't mount an immune response. The importance of unresponsiveness is difficult to assess since high enough doses have not been widely employed to date.
The term unresponsive is useful since resistance is often taken to imply parasite resistance which is not necessarily the case. Patients with fatal antimony unresponsive kala-azar had parasites which showed a normal response to antimonials in animal models indicating ahostdefect2^ 32 O n th e o th e rh a n d a tle a st in Kenyan kala-azar there is evidence in cell cultures^ and in animal models of parasite resistance to a n t i m o n y 3 3 . Unfortunately similar experiments have not be possible with Lbb since it cannot be induced to grow in in vivo cell lines. H owever M oreira43 has examined one of our most suspect Lbb isolates in terms of resistance and it shows diminished sensitivity in her promastigote culture system. The W orld H ealth O rganization1 suggests we consider primary unresponsiveness as no clinicai or parasitological improvement on initial therapy and secondary unresponsiveness where relapse occurs after one or more courses of apparently successful treatm ent To illustrate how difficult it is to discuss this subjet with the recent changes in dosage sche dules índia which recorded a 13% relapse rate in kala-azar is said to have reduced it to zero by doubling the antimony dose1. Certainly a risk of minimal dose therapy is the emergence of parasite resistance to antimonial treatment.
Concluding remarks
The last two decades have seen great advances in our understanding of the taxonomy of Leishmania using biochemical29 and im m unological^ methods. Today this is seen as an essential first step to unravelling the complexities of the epidemiology and clinicai picture o f human disease. A t the University of Brasília we were the first to use the monoclonal technology developed at H arvard in such field studies17. W e are dealing in T rês Braços, Bahia, with what appears to be virtually a m onotransmission to m an of Lbb. W e are still defining the clinicai picture based on this taxonomy. Similar data on other important parasites in Brazil such as L eishm ania braziliensis guyanensis will doubtless be available soon. N ew clinicai entities are being defined; for example we are preparing a report on disseminated cutaneous leishmanisis caused by L bb16.
In contrast to this exciting field in epidemiology, prospects for advances in the chemotherapy of leismaniasis are gloomy. I never imagined when I qualified in medicine 25 years ago that I would review antimonial therapy in 1985. H eavy metal therapy was the mainstay of 19t*1 century medicine. The experts in this field today are physicians treating leishmaniasis. There has been no advance in drug formulations for primary therapy that has benefited the patient for forty years. Parental pentavalent antimonials are still the drugs of choice for m ost of the forms of leishmaniasis.
I will not discuss why this is so, although I have definite views after confronting hundreds of patients with Lbb infections and often not having even antimony to offer them. Let us adopt a more positive approach. The fact is that there is only one pharmaceutical com pany and one research institute seriously involved in developing new drugs; namely the W ellcome Research Laboratories in A m erica and England and the W alter Reed Arm y Institute of M edicai Research in W ashington. Two drugs, an 8 aminoquinoline (W R 6 0 2 6 ), 0 from the latter and Allopurinol riboside from the former47 have entered clinicai trials. Preliminary information suggests that neither m ay be suitable for our problems with Lbb, but even if this is not so, I may well be an old m an before I see such oral preparations used in our field clinic. This is because clinicai evaluation is a lengthy process and involves testing initially in kala-azar and limited skin leishmaniasis before it can be used for an organism causing metastatic disease. A lso we ourselves routinely do a trial in hospital in Brasília before a drug can be taken to the field. The evaluation o f each of these trials will take several years.
A nother possibility is the use o f liposome linked antimony which has given promising result in ani m ais11. There is some evidence that this is more effective in cutaneous lesions than the free drug^. The one patient with K enyan kala-azar unresponsive to free antimony treated with liposomés failed to respond35. Both the research groups mentioned are involved in this development. Although if it ever came to human trial this approach would still imply injection therapy it would abolish the need for these painful, prolonged, injection schedules. Ih av e n o d o u b t that the single most important advance in the control of leishmaniasis is the development of more efficient drug therapy38 in terms o f an oral inexpensive treatm ent of short duration. Such a drug would be equally useful both in kala-azar and in the mucocutaneous infections of rural areas. W ith ministry support we are currently testing ketoconazole but this hardly falls into this category.
The last word is perhaps better said by the father of one of our patients in the endemic area of Três Braços where they are as familiar with G lucantim e as we are with aspirin48. H e asked me why if we had been working there for ten years we were still using this drug and had not found a more convenient therapy. I explained that we were dependent in the field, at the end of the line as it were, on the research of other colleagues and nothing had appeared to date. " But will it" , he insisted " so that I don't have to walk 5 kilometres with my daughter to get her injection?" R E F E R E N C E S 18. Cuce LC, Freitas T H P , Oliveira Z N P, Sampaio SAP. 
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